Pulmonary Hypertension in Interstitial Lung Disease
CHEST · 2024-10 · 166 (4) · 778-792
DOI: 10.1016/j.chest.2024.04.025 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift CHEST, 2024-10. Verfasst von Hui Li Ang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Royal Melbourne Hospital, VIC, Australia; Institute for Breathing and Sleep, VIC, Australia. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Lung Diseases, Interstitial. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 109 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Pulmonary hypertension (PH) is a key complication in interstitial lung disease (ILD), with recent therapeutic advances. RESEARCH QUESTION: What are the diagnostic evaluation, epidemiologic features, associated factors, prognostic significance, and outcome measures in interventional trials for PH in patients with ILD in the current literature? STUDY DESIGN AND METHODS: The Ovid MEDLINE, Embase, and CENTRAL databases were searched for original research evaluating PH in participants with ILD of any cause. The definition of PH was based on the investigators' criteria. RESULTS: Three hundred two studies were included, with varying diagnostic evaluations used to define PH. Commonly used diagnostic tests were right heart catheterization (56%) and transthoracic echocardiography (50%). The pooled prevalence for PH in general populations with ILD was 36% (95% CI, 30%-42%) using right heart catheterization and 34% (95% CI, 29%-38%) using transthoracic echocardiography. Lower diffusion capacity of the lungs for carbon monoxide, worse oxygenation status, reduced exercise capacity, increased pulmonary artery to aorta ratio and pulmonary artery diameter, and elevated serum brain natriuretic peptide consistently were associated with the presence of PH in at least 60% of reported studies. The presence of PH was associated with increased symptom burden and worse prognosis. Outcome measures in interventional trials of PH in ILD focused on changes in pulmonary vascular hemodynamics and 6-min walk distance. INTERPRETATION: PH is a common complication in ILD with significant health impacts. A standardized definition with prospective evaluation of risk-stratified assessments for PH using identified associated risk factors is warranted. Our findings provide an evidence base for validation as surrogate end points in future PH interventional trials in ILD. TRIAL REGISTRY: International Prospective Register of Systematic Reviews; No.: CRD42021255394; URL: https://www.crd.york.ac.uk/prospero/.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Royal Melbourne Hospital, VIC, Australia; Institute for Breathing and Sleep, VIC, Australia.
- Institute for Breathing and Sleep, VIC, Australia.
- Department of Cardiology, Western Health, St. Albans, VIC, Australia.
- Royal Sussex County Hospital, Brighton, England.
- Department of Respiratory and Sleep Disorders Medicine, Western Health, St. Albans, VIC, Australia.
- University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, Vancouver, BC, Canada.
Zitieren
APA
Ang, H. L., Schulte, M., Chan, R. K., Tan, H. H., Harrison, A., Ryerson, C. J., & Khor, Y. H. (2024). Pulmonary Hypertension in Interstitial Lung Disease. CHEST, 166(4), 778-792. https://doi.org/10.1016/j.chest.2024.04.025
Vancouver
Ang HL, Schulte M, Chan RK, Tan HH, Harrison A, Ryerson CJ, et al. Pulmonary Hypertension in Interstitial Lung Disease. CHEST. 2024;166(4):778-792. doi:10.1016/j.chest.2024.04.025
BibTeX
@article{Ang2024,
author = {Ang, Hui Li and Schulte, Max and Chan, Roseanne Kimberley and Tan, Hann Hsiang and Harrison, Amelia and Ryerson, Christopher J and Khor, Yet Hong},
title = {Pulmonary Hypertension in Interstitial Lung Disease},
journal = {CHEST},
year = {2024},
volume = {166},
number = {4},
pages = {778--792},
doi = {10.1016/j.chest.2024.04.025}
}
EUVIMED